A Bioactive Polymer Designed for Cardiac Assist Devices

Information

  • Research Project
  • 6690629
  • ApplicationId
    6690629
  • Core Project Number
    R43HL074531
  • Full Project Number
    1R43HL074531-01
  • Serial Number
    74531
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/30/2003 - 20 years ago
  • Project End Date
    8/31/2004 - 19 years ago
  • Program Officer Name
    LUNDBERG, MARTHA
  • Budget Start Date
    9/30/2003 - 20 years ago
  • Budget End Date
    8/31/2004 - 19 years ago
  • Fiscal Year
    2003
  • Support Year
    1
  • Suffix
  • Award Notice Date
    9/29/2003 - 20 years ago
Organizations

A Bioactive Polymer Designed for Cardiac Assist Devices

DESCRIPTION (provided by applicant): The ultimate objective of this proposal is the development of a novel, bioactive polymer for use in ventricular assist devices (VAD), and other long-term blood contacting implantable devices. Although VADs are becoming an important therapeutic option for patients in heart failure, serious problems persist secondary to thromboembolic complications and continue to be a challenge at times to clinicians, despite aggressive anti-coagulation regimens. Anti-coagulant (i.e., heparin) coatings are currently being used for short-term use. These coatings either dissolve rapidly, or are eventually covered by proteins resulting in reduced bioactivity. The polymer developed here will provide a slow, in situ release or anti-coagulants at the blood: surface interface, thereby changing the local coagulation properties. The bioactive polymer will be optimized, and characterized in Phase I. Preliminary studies have demonstrated that anti-coagulants can be incorporated in to a biomedical polyurethane currently used in several different cardiac assist devices. An optimal polymer formulation, based on key properties for use in a VAD design will be developed. The release rates of the anti-coagulant from the polymer will also be measured. Key components manufactured from the bioactive polymer will be tested for long-term use to determine any impact on the overall device reliability. Finally, several prototype VADs will be built to demonstrate that current manufacturing procedures are transferable to the bioactive polymer. The Phase I study will demonstrate the compatibility of the bioactive polymer with a VAD design. Phase II will primarily involve testing of a VAD constructed with the polymer. Readiness testing will be completed to verify the long-term device reliability. This will include detailed pre-clinical animal studies to determine the benefits of the use of a bioactive polymer for long-term VAD implantation.

IC Name
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
  • Activity
    R43
  • Administering IC
    HL
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    99978
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    837
  • Ed Inst. Type
  • Funding ICs
    NHLBI:99978\
  • Funding Mechanism
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ABIOMED, INC.
  • Organization Department
  • Organization DUNS
    050636737
  • Organization City
    DANVERS
  • Organization State
    MA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    01923
  • Organization District
    UNITED STATES